Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)

Shitara K.; Fleitas T.; Kawakami H.; Curigliano G.; Narita Y.; Wang F.; Wardhani S.O.; Basade M.; Rha S.Y.; Wan Zamaniah W.I.; Sacdalan D.L.; Ng M.; Yeh K.H.; Sunpaweravong P.; Sirachainan E.; Chen M.-H.; Yong W.P.; Peneyra J.L.; Ibtisam M.N.; Lee K.-W.; Krishna V.; Pribadi R.R.; Li J.; Lui A.; Yoshino T.; Baba E.; Nakayama I.; Pentheroudakis G.; Shoji H.; Cervantes A.; Ishioka C.; Smyth E.
Shitara, K. (12764260600); Fleitas, T. (24070244600); Kawakami, H. (53663802900); Curigliano, G. (57221578995); Narita, Y. (55839842000); Wang, F. (57192698934); Wardhani, S.O. (57193196381); Basade, M. (8088436500); Rha, S.Y. (7006023235); Wan Zamaniah, W.I. (57197752505); Sacdalan, D.L. (57193522866); Ng, M. (56693812000); Yeh, K.H. (7201438906); Sunpaweravong, P. (6508227376); Sirachainan, E. (6602792356); Chen, M.-H. (58434745100); Yong, W.P. (58910827500); Peneyra, J.L. (58910632700); Ibtis
12764260600; 24070244600; 53663802900; 57221578995; 55839842000; 57192698934; 57193196381; 8088436500; 7006023235; 57197752505; 57193522866; 56693812000; 7201438906; 6508227376; 6602792356; 58434745100; 58910827500; 58910632700; 58910037700; 57219957155; 58349814100; 57194732282; 57190345301; 58911235000; 57205400013; 7005105717; 56653172200; 56230606500; 36440260400; 57535599600; 7005354286; 36103192800
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
2024
ESMO Open
9
2
102226
2
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, Valencia, Spain; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan; Istituto Europeo di Oncologia, IRCCS, Milan; Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Mainland China, Guangzhou, China; Department of Internal Medicine Division of Medical Hematology-Oncology, Brawijaya University, Dr. Saiful Anwar General Hospital Malang, East Java, Indonesia; Department of Medical Oncology, Jaslok Hospital and Breach Candy Hospital, Mumbai, India; Department of Internal Medicine, Yonsei University College of Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea; Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Division of Medical Oncology, Department of Medicine, University of the Philippines, The Philippines, Manila, Philippines; Department of GI Oncology, National Cancer Centre Singapore, Singapore, Singapore; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan; Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand; Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore; St. Peregrine Oncology Unit, San Juan de Dios Hospital, The Philippines, Pasay City, Philippines; Institute of Radiotherapy and Oncology, General Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea; Department of Medical Oncology, AIG Hospital, Hyderabad, India; Division of Gastroenterology, Pancreatobiliary Oncology and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Oncology, University of Tongji, Shanghai East Hospital, Mainland China, Shanghai, China; Section of Medical Oncology, Department of Internal Medicine, Southern Philippines Medical Center ESM, The Philippines, Davao City, Philippines; Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; ESMO, Lugano, Switzerland; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain; Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan; Department of Oncology, Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom
Shitara K., Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Fleitas T., Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, Valencia, Spain; Kawakami H., Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan; Curigliano G., Istituto Europeo di Oncologia, IRCCS, Milan, Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy; Narita Y., Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; Wang F., Department of Medical Oncology, Sun Yat-sen University Cancer Center, Mainland China, Guangzhou, China; Wardhani S.O., Department of Internal Medicine Division of Medical Hematology-Oncology, Brawijaya University, Dr. Saiful Anwar General Hospital Malang, East Java, Indonesia; Basade M., Department of Medical Oncology, Jaslok Hospital and Breach Candy Hospital, Mumbai, India; Rha S.Y., Department of Internal Medicine, Yonsei University College of Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea; Wan Zamaniah W.I., Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Sacdalan D.L., Division of Medical Oncology, Department of Medicine, University of the Philippines, The Philippines, Manila, Philippines; Ng M., Department of GI Oncology, National Cancer Centre Singapore, Singapore, Singapore; Yeh K.H., Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan; Sunpaweravong P., Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand; Sirachainan E., Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Chen M.-H., Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; Yong W.P., Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore; Peneyra J.L., St. Peregrine Oncology Unit, San Juan de Dios Hospital, The Philippines, Pasay City, Philippines; Ibtisam M.N., Institute of Radiotherapy and Oncology, General Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; Lee K.-W., Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea; Krishna V., Department of Medical Oncology, AIG Hospital, Hyderabad, India; Pribadi R.R., Division of Gastroenterology, Pancreatobiliary Oncology and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Li J., Department of Oncology, University of Tongji, Shanghai East Hospital, Mainland China, Shanghai, China; Lui A., Section of Medical Oncology, Department of Internal Medicine, Southern Philippines Medical Center ESM, The Philippines, Davao City, Philippines; Yoshino T., Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Baba E., Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Nakayama I., Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Pentheroudakis G., ESMO, Lugano, Switzerland; Shoji H., Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; Cervantes A., Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain; Ishioka C., Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan; Smyth E., Department of Oncology, Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer (GC), published in late 2022 and the updated ESMO Gastric Cancer Living Guideline published in July 2023, were adapted in August 2023, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with GC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with GC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), coordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian regions represented by the 10 oncological societies. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with GC across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies, between the different regions of Asia. © 2024 The Author(s)
ESMO; gastric cancer; guidelines; Pan-Asian; treatment
Asia; Follow-Up Studies; Humans; Medical Oncology; Societies, Medical; Stomach Neoplasms; cisplatin; docetaxel; epidermal growth factor receptor 2; fluoropyrimidine; gimeracil plus oteracil potassium plus tegafur; irinotecan; oxaliplatin; pembrolizumab; platinum derivative; trastuzumab deruxtecan; adaptation; Article; cancer adjuvant therapy; cancer chemotherapy; cancer diagnosis; cancer staging; cancer surgery; cancer therapy; China; clinical trial (topic); consensus; drug approval; epidemiological data; follow up; histopathology; human; India; Indonesia; Japan; Korea; Malaysia; managed care; methodology; molecular biology; monotherapy; oncology; perioperative care; phase 3 clinical trial (topic); Philippines; practice guideline; public health service; radical gastrectomy; reimbursement;
Elsevier B.V.
20597029
38458658
Article
Q1
2196
1106